Sitaxsentan, a highly selective endothelin-A (ET-A) receptor antagonist undergoing FDA review as an alternative to bosentan for pulmonary arterial hypertension (PAH) treatment, demonstrated improved efficacy over bosentan in a recent study.
Sitaxsentan, a highly selective endothelin-A (ET-A) receptor antagonist undergoing FDA review as an alternative to bosentan for pulmonary arterial hypertension (PAH) treatment, demonstrated improved efficacy over bosentan in a recent study.
"Sitaxsentan is 6,500 times more selective for the ET-A receptor than bosentan," said David Langleben, MD, Professor of Medicine, McGill University, Montreal, Quebec, Canada during the 71st annual scientific meeting of the American College of Chest Physicians.
Sitaxsentan requires once-daily dosing and ongoing trials have demonstrated it may be especially beneficial for patients with PAH due to connective tissue disease, researchers reported.
Overall, patients taking the 100 mg dose (n=115) had significantly greater time to clinical worsening (P=.0345) than those taking placebo (n=119). Clinical worsening was defined as death, transplantation, epoprostenol use, or atrial septostomy in one trial and as death, transplantation, atrial septostomy, additon of a new chronic PAH treatment, hospitalization for worsening PAH, or a combined deterioration in WHO functional class and $15% decrease from baseline in 6-minute walk distance in the second.
In addition, interim results of a 1-year, phase 3 extension study randomizing 145 patients to 100 mg sitaxsentan once daily or 125 mg bosentan twice daily demonstrated significantly fewer liver function abnormalities in the sitaxsentan group (P=.014).
James Seibold, MD, director, University of Michigan Scleroderma Program, Ann Arbor, Mich, presented results seen in 110 patients with PAH due to connective tissue disease included in placebo-controlled sitaxsentan trials. A total of 63 had systemic sclerosis, 25 had systemic lupus erythematosis, and 22 had other connective tissue diseases. Patients with a total lung capacity of less than 80% or a 6-minute walk distance greater than 450 m at baseline were excluded.
Dr Seibold reported that patients taking the 100-mg dose of sitaxsentan demonstrated a 21-m improvement in 6-minute walk distance after 6 weeks of therapy and the improvement was sustained through 18 weeks (P=.042).
Sitaxsentan also appeared improve New York Heart Association (NYHA) functional class among connective tissue disease patients with PAH. In one long-term extension study, 42 of 178 PAH patients were identified with connective tissue disease and NYHA Class II or III heart failure at baseline. After up to 55 weeks treatment with either 100 or 300 mg sitaxsentan, 65% of patients taking the 100-mg dose and 43% of patients taking the 300 mg dose demonstrated improvement in functional class.
Among those in the 100-mg group, 70% had Class III and 30% had Class II heart failure at baseline. At the end of the study, 40% had Class III, 55% had Class II, and 5% had Class I heart failure.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.